top of page

Our Sources

Text Sources

[1] Landau, Elizabeth. “Why Pancreatic Cancer Is so Deadly.” CNN, Cable News Network, 9 Nov. 2020, 


[2] “Immunotherapy for Pancreatic Cancer.” Edited by O'Hara Mark, Cancer Research Institute, 


[3] “Pancreatic Cancer Facts.” Hirshberg Foundation for Pancreatic Cancer Research, 28 Jan. 2021, 


[4] J. Ferlay, C. Partensky & F. Bray (2016) More deaths from pancreatic cancer than breast cancer in the EU by 2017,Acta Oncologica, 55:9-10, 1158-1160, DOI: 10.1080/0284186X.2016.1197419 <>


[5] Jim Stallard Tuesday, November 8. “Why Is Pancreatic Cancer So Hard to Treat?” Memorial Sloan Kettering Cancer Center, 8 Nov. 2016, 


[6] “Second Cancers Related to Treatment.” American Cancer Society, 


[7] “Checkpoint Inhibitors.” Checkpoint Inhibitors | Types of Immunotherapy | Cancer Research UK, 27 Jan. 2021, 


[8] Wang, Xiaodong, et al. “Tumor Cell-Intrinsic PD-1 Receptor Is a Tumor Suppressor and Mediates

Resistance to PD-1 Blockade Therapy.” PNAS, National Academy of Sciences, 24 Mar. 2020,<,in%20some%20types%20of%20cancers.> 


[9] Forster, Victoria. “Resistance to Immune Checkpoint Inhibition in Pancreatic Cancer.” Cancer Therapy Advisor, 26 Dec. 2019, 


[10] Chang, Thomas Ming Swi. “50th Anniversary of Artificial Cells: Their Role in Biotechnology, Nanomedicine, Regenerative Medicine, Blood Substitutes, Bioencapsulation, Cell/Stem Cell Therapy and Nanorobotics.” Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, U.S. National Library of Medicine, 2007, 


[11] Bozzuto, Giuseppina, and Agnese Molinari. “Liposomes as Nanomedical Devices.” International Journal of Nanomedicine, Dove Medical Press, 2 Feb. 2015, 


[12] Bulbake, Upendra, and Doppalaupdi, Sindhu, and Kommieni, Nagavendra and, Khan, Wahid. “Liposomal Formulations in Clinical Use: An Updated Review.” Pharmaceutics, MDPI, 27 Mar. 2017, 


[13] EA. Forssen, ZA. Tokes, et al. “A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form.” Drug Safety, Springer International Publishing, 1 Jan. 1979, 


[14] Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. doi:10.1038/nrd1632 <>


[15] Fanciullino, Raphaelle, et al. “COVID-19 Vaccine Race: Watch Your Step for Cancer Patients.” Nature News, Nature Publishing Group, 7 Dec. 2020, <>


[16] “Pancreatic Cancer - Statistics.” Cancer.Net, 16 July 2020,,disease%20will%20occur%20this%20year. 


[17] Qu, C. F., Li, Y., Song, Y. J., Rizvi, S. M. A., Raja, C., Zhang, D., … Allen, B. J. (2004). MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate. British Journal of Cancer, 91(12), 2086–2093.doi:10.1038/sj.bjc.6602232 <>

[18] Nath, S., & Mukherjee, P. (2014). MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends in Molecular Medicine, 20(6), 332–342.doi:10.1016/j.molmed.2014.02.007 <>

[19] Eloy, J. O., Petrilli, R., Trevizan, L. N. F., & Chorilli, M. (2017). Immunoliposomes: A review on functionalization strategies and targets for drug delivery. Colloids and Surfaces B: Biointerfaces, 159, 454–467. doi:10.1016/j.colsurfb.2017.07.085 <>


[20] Topham, N. J., & Hewitt, E. W. (2009). Natural killer cell cytotoxicity: how do they pull the trigger? Immunology, 128(1), 7–15.doi:10.1111/j.1365-2567.2009.03123.x <>

[21] Stow, J. L., Manderson, A. P., & Murray, R. Z. (2006). SNAREing immunity: the role of SNAREs in the immune system. Nature Reviews Immunology, 6(12), 919–929.doi:10.1038/nri1980 <>

[22] “Resources.” Perforin/Granzyme Apoptosis Pathway - Creative Diagnostics,,being%20appropriately%20delivered%20by%20perforin. 

[23] Yadav, Durgavati, et al. “Liposomes for Drug Delivery.” OMICS International, OMICS International, 6 Nov. 2017, 

[24] Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 975.doi:10.2147/ijn.s68861 <>

[25] Shi, Yang, et al. “The EPR Effect and beyond: Strategies to Improve Tumor Targeting and Cancer Nanomedicine Treatment Efficacy.” Theranostics, Ivyspring International Publisher, 25 June 2020, 

[26] Rao, Jianghong, et al. “Fluorescence Imaging in Vivo: Recent Advances.” Current Opinion in Biotechnology, U.S. National Library of Medicine, 


[27] Romberg, B., Oussoren, C., Snel, C. J., Hennink, W. E., & Storm, G. (2007). Effect of Liposome Characteristics and Dose on the Pharmacokinetics of Liposomes Coated with Poly(amino acid)s. Pharmaceutical Research, 24(12), 2394–2401.doi:10.1007/s11095-007-9393-2 <>


[28] Sercombe, Lisa, et al. “Advances and Challenges of Liposome Assisted Drug Delivery.” Frontiers, Frontiers, 16 Nov. 2015, 


[29] “CAR T-Cell Therapy and Its Side Effects.” American Cancer Society, 


[30] Beer, Gabriella. “Why Doesn't the Immune System Attack Cancer Cells? Science Surgery:” Cancer Research UK - Science Blog, 1 Mar. 2019, 


[31] Li, S., Jiang, Q., Liu, S., Zhang, Y., Tian, Y., Song, C., … Zhao, Y. (2018). A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo. Nature Biotechnology, 36(3), 258–264. doi:10.1038/nbt.4071 <>

[32] “DNA Aptamers or RNA Aptamers?” Base Pair Biotechnologies, 19 Jan. 2020, 

[33] Sato, Y., Hiratsuka, Y., Kawamata, I., Murata, S., & Nomura, S. M. (2017). Micrometer-sized molecular robot changes its shape in response to signal molecules. Science Robotics, 2(4), eaal3735.doi:10.1126/scirobotics.aal3735 <>


[34] Rawla, Prashanth, et al. “Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors.” World Journal of Oncology, Elmer Press, Feb. 2019, 

[35] Noble, G. T., Stefanick, J. F., Ashley, J. D., Kiziltepe, T., & Bilgicer, B. (2014). Ligand-targeted liposome design: challenges and fundamental considerations. Trends in Biotechnology, 32(1), 32–45. doi:10.1016/j.tibtech.2013.09.007 <>

[36] “T Cell Macrophage Interactions.” T Cells and Macrophages, 

[37] Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. doi:10.1038/nrd1632 <>

Image Sources

[1] Images not in the source list are created through BioRender and Powerpoint - <>  or from Wix Gallery

[2]  Home Page:Page  Background - <>

[3] History of the Field: Doxil Image - <>

[4] History of the Field: Liposome Image - <>

[5] History of the Field: Synthetic Cell - <>

[6] History of the Field: Increase in Research Image -<

2018.1429356 >

[7] History of the Field: Liposome Closeup Image <>

[8] Present Technology: What is Cancer Image  - <>

[9] Present Technology: Immunotherapy - <>

[10] Our Solution: Page Background -  <>

[11] Our Solution: Overview of Lykosa - <>

[12] Consequences: Page Background - <>

[13] Consequences: Square Purple Background - <>

[14] Breakthroughs: Page Background - <>

[15] Breakthroughs: Fluorescence Imaging - <>

logo_white_background copy.png
bottom of page